Kevin O'Leary

Kevin O'Leary roastuje Twój portfel

22 sierpnia 2026

Mr. Wonderful's Verdict: Why Your ETF Overlap Is Killing Returns

Ocena

6,5/10

T…
17 aktywów

Sektor i rodzaj aktywów

Szeroki rynek (indeksy/ETFy)69,1%
Ochrona zdrowia10,2%
Finanse7,1%
Pozostałe13,7%

Region

Ameryka Północna (rozwinięta)55,6%
Globalny / zdywersyfikowany39,0%
Europa (rozwinięta)5,0%
Rezerwy gotówkowe0,5%

Strategia

Fundament (stabilny)36,0%
Dochód (dywidendy)31,7%
Wzrost (agresywny)27,7%
Pozostałe4,7%

Największe pozycje wg wagi

1
Invesco EQQQ NASDAQ-100 UCITS ETF
EQQQ
18,2%
2
Vanguard S&P 500 UCITS ETF
VUSA.L
11,1%
3
Vanguard FTSE All-World UCITS ETF
VWRL.L
9,5%
4
iShares World Equity High Income Active UCITS ETF USD Inc
WINC
7,7%
5
HSBC Multi Factor Worldwide Equity UCITS ETF
HWWA
7,6%
6
Tarsus Pharmaceuticals, Inc.
TARS
5,1%
7
Vanguard FTSE All-World High Dividend Yield UCITS ETF USD Distributing
VHYL.L
5,1%
8
iShares UK Dividend UCITS ETF GBP (Dist)
IUKD.L
5,0%
9
LEGAL & GENERAL UCITS ETF PUBLI
LDGG
4,9%
10
Visa Inc.
V
4,4%
Rezerwy gotówkowe
0,5%

Meet Your Commanding Officer

Listen to me. Every single dollar you have is a soldier. Your only job in life is to send them out onto the battlefield of the global market and demand they capture prisoners and bring them back to you. I don't care about your feelings, and I don't care about the story. I only care about one thing: does this portfolio pay you?

Right now, your account is brand new. You have zero months of real history here, so we aren't going to talk about your unrealized 1.5% bump. It means absolutely nothing yet. Anyone can get lucky for a few weeks. Instead, I'm looking at the blueprint you've built. I'm looking at the squad you've assembled to see if they actually have what it takes to compound wealth, or if you're just throwing spaghetti at the wall.

You have some good instincts here, but you also have a lot of noise. Let's tear it down and see if we can turn this into a real cash-generating machine.

The Anatomy of a Cash-Generating Machine

I look at your sector breakdown, and I see almost 70% of your money parked in broad market indexes and ETFs. I like that. You aren't trying to be a cowboy with the majority of your capital. You have 36% of your strategy labeled as "Core" and nearly 32% dedicated to "Income." That tells me you understand the fundamental truth of investing: cashflow is king. You own names like Visa, a spectacular business that essentially taxes the global economy and prints cash, and you've got dividend-focused vehicles like IUKD and VHYL doing the heavy lifting.

Now, let's talk about your cash position. You are sitting on a microscopic 0.49% in cash reserves. On one hand, I love it. Idle cash is a lazy soldier sitting in the barracks picking his nose. Your money is out there working. But on the other hand, you have absolutely zero dry powder. The 10-year Treasury is sitting around 4.65%. You can actually get paid to wait right now. Having less than one percent in cash means if the market drops tomorrow and hands you a 20% discount on great dividend-paying stocks, you are completely paralyzed. You have no ammunition to take advantage of the blood in the streets.

You have 56% of your exposure in North America and 39% global. That's a decent geographic spread. But the way you are executing it is sloppy, and it's time we address the mess.

Where Your Soldiers Are Dying

ETF Overlap Madness

Your top holding is the EQQQ Nasdaq 100 ETF at 18.3%. Then you hold the Vanguard S&P 500 (VUSA) at 11.2%, the All-World ETF (VWRL) at 9.6%, and an HSBC Multi-Factor ETF at 7.7%. Do you realize what you are doing? You are buying the exact same mega-cap tech stocks over and over again in different wrappers. You're paying different fees to own the same companies. It's redundant and it creates a false sense of diversification.

Speculative Biotech Flyers

You have 5.1% of your portfolio in Tarsus Pharmaceuticals (TARS). It's your biggest single stock pick. Yes, it's currently your best performer, up around 18%. But it's a biotech. These things are binary—they either get approval and moon, or they fail a trial and go to zero. Hope is not a strategy. I sold The Learning Company to Mattel for $4.2 billion because I knew when to take the money and run. Do not fall in love with a speculative stock just because it gave you a quick pop. If it doesn't pay a dividend, it's a gamble.

Pointless Clutter

You have 17 distinct positions, and several of them—like Cardinal Health, Millrose Properties, and S&P Global—are sitting at under 3% of your portfolio. Why do you own these? If a stock is only 1.8% of your money, even if it doubles, it barely moves the needle for your overall wealth. If you don't have the conviction to put at least 4% or 5% into a name, get rid of it.

Mr. Wonderful's Bottom Line

I'll give this portfolio a 6.5 out of 10. The foundation is there. You understand the value of ETFs and you clearly want dividend income. But you've cluttered your account with redundant funds and tiny, meaningless stock positions.

Here is what you need to do to fix this:

1. Consolidate your ETFs. Pick your core index fund and stick to it. Stop buying four different global and US funds that overlap by 60%. Pick the one with the lowest fee, sell the rest, and deploy the capital cleanly.

2. Take profits on the biotech. TARS gave you a nice 18% gift. Take the original capital off the table and let the house money ride, or sell it all. Don't let a pharma stock turn into a permanent zero in your account.

3. Build a cash reserve. Raise your cash balance to at least 5%. You need flexibility to buy the dips.

4. Clean up the sub-3% trash. Liquidate the tiny positions that don't matter. Concentrate your individual stock picks into 5% blocks of high-quality, dividend-paying companies.

Remember, I'm not here to be your friend. I'm here to make sure your soldiers don't get slaughtered. Stop playing around, clean up the overlap, and demand that every single position pays you.

O tej analizie

Ten roast portfela został wygenerowany przez AI PortfolioGlance, analizując Twój portfel z perspektywy Kevin O'Leary. Analiza ocenia alokację aktywów, koncentrację sektorową, dywersyfikację geograficzną, czynniki ryzyka i dostarcza konkretne rekomendacje.

To jest analiza edukacyjna wygenerowana przez AI, nie porada finansowa. Zawsze konsultuj się z wykwalifikowanym doradcą finansowym przed podjęciem decyzji inwestycyjnych.

Więcej ocen portfeli

← Powrót do roastów